181 reports of this reaction
1.6% of all ENTACAPONE reports
#15 most reported adverse reaction
HALLUCINATION, VISUAL is the #15 most commonly reported adverse reaction for ENTACAPONE, manufactured by Ajanta Pharma USA Inc.. There are 181 FDA adverse event reports linking ENTACAPONE to HALLUCINATION, VISUAL. This represents approximately 1.6% of all 11,238 adverse event reports for this drug.
Patients taking ENTACAPONE who experience hallucination, visual should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION, VISUAL is a less commonly reported adverse event for ENTACAPONE, but still significant enough to appear in the safety profile.
In addition to hallucination, visual, the following adverse reactions have been reported for ENTACAPONE:
The following drugs have also been linked to hallucination, visual in FDA adverse event reports:
HALLUCINATION, VISUAL has been reported as an adverse event in 181 FDA reports for ENTACAPONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION, VISUAL accounts for approximately 1.6% of all adverse event reports for ENTACAPONE, making it a notable side effect.
If you experience hallucination, visual while taking ENTACAPONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.